Figure S2 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S2. Lurbinectedin sensitivity (IC50) correlation with MYC expression and changes in expression of NE markers.
KI fragen
Like
Bookmark
Share
KI fragen
Like
Bookmark
Share
Figure S2 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways. | Synapse